Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URANUS trial: Neoadjuvant versus adjuvant chemotherapy in upper tract urothelial carcinoma
2016-004017-27Phase 2Active
- Sponsor
- European Uro-Oncology Group
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cisplatin, gemcitabine, methotrexate, vinblastine and doxorubicin in upper tract urothelial carcinoma (UTUC) (2 arms), sponsored by European Uro-Oncology Group. Primary endpoint: Feasibility of planned chemotherapy completion. Started Mar 2017; status: active.
02
Drugs
cisplatingemcitabinemethotrexatevinblastinedoxorubicin
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on 2016-004017-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004017-27.